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ABSTRACT 
 
Cyclosporine (CSA) is a highly potent immunosuppressant drug and has been used to 
treat rheumatoid arthritis, psoriasis, organ rejection post-transplant, and chronic dry eye disease. 
The objective of this investigation was to increase the CSA residence time on the ocular surface 
using solid lipid nanoparticles (SLNs) and its in-situ gel formulation (CSA-SLN-IG), for 
treatment of dry eye disease. CSA loaded SLNs (CSA-SLN) were prepared with the 
homogenization method, using Precirol ® ATO 5 as a solid lipid and Tween® 80 and Poloxamer 
188 as surfactants. Prepared SLNs were optimized based on particle size, zeta potential (ZP), 
PDI, assay and stability. CSA-SLN in-situ gels (CSA-SLN-IG) were developed using gellan gum 
as the gelling agent and rheological properties were evaluated. DSC analysis showed that there 
was no interaction between lipid and drug. Optimized CSA-SLN showed the particle size, PDI, 
ZP and assay to be121.20± 5.20 nm, 0.4 ±0.04, -24 ± 1, 95 ± 0.5% respectively. CSA-SLN was 
stable at refrigerated and room temperature conditions over one month and no significant 
changes were observed before and after autoclaving up to one month. CSA-SLN-IG prepared 
with 0.3% gellan gum showed immediate gel formation with a gel residence time of more than 
24 hours, the viscosity of 27.90± 2.80 cP and an assay of 85 ± 0.5%.Therefore, CSA-SLN and 
CSA-SLN-IG could be considered as an alternative approach for dry eye disease. 
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CHAPTER I 
INTRODUCTION 
 
Dry eye disease (DED) or kerratoconjunctivitis sicca (KCS) is a disease which is 
characterized by unstable tear film which is caused either by tear film deficiency (Aqueous dry 
eye disease) or excessive evaporation of tear film (evaporative dry eye disease). Site of action for 
DED is mainly extraocular organs like cornea, lacrimal glands and conjunctiva. Cyclosporine A 
(CSA)  has been known to treat aqueous dry eye disease by acting as a T-cell inhibitor and thus 
decreasing interleukin-2 production which is known marker of dry DED (Ames and Galor 2015). 
CSA is a cyclic undecapeptide with a very high molecular weight of 1202.61 g/mol. Its 
cyclic structure and lipophilic characteristic gives it a high stability (Kumar, Singhal, and Singh 
2001). It is a highly hydrophobic drug with very poor water solubility of about 0.012 mg/mL at 
25°C (Mondon et al. 2011). CSA is a powerful immunosuppressive agent and has been used in 
the treatment of dry eye disease. 
Solid lipid nanoparticle (SLNs) is dispersions of solid lipid in water and allows loading of 
both hydrophilic and hydrophobic active ingredients. They are a colloidal carrier system for 
controlled drug delivery. The solid matrix protects the active ingredients against chemical 
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degradation and provides long term stability and flexibility in drug release profile 
designs. High lipid solubility of the drug means high encapsulation efficiency of the formulation 
(Patel, Kesharwani, and Gupta 2013). SLNs have been known to enhance the bioavailability of 
drug when applied topically in ophthalmology (Qaddoumi et al. 2004). 
In-situ gels are solutions under normal conditions but undergo sol-to-gel conversion only when 
they come in contact with certain conditions like pH, temperature or physiological fluids 
(Agrawal, Das, and Jain 2012). The gel formed helps in control drug release by increasing the 
residence time of formulation on the cornea, and thus decreasing loss caused by tear flow and 
blinking. The gelation mechanism depends on the type of gelling agent used. 
A CSA formulation available in the market for the treatment of DED is Restasis® 
(Allergan) which is 0.05%w/v CSA emulsion. Recently another formulation Cequa® (Sun 
Pharma) has been approved by the US FDA for treatment of DED. It is a nano-micellar 
formulation with 0.09% w/v drug load.  
Various modes of deliveries for CSA have been attempted but each delivery method 
has a certain drawback. Topical delivery of CSA has been seen advantageous with fewer side 
effects as compared to systemic delivery(Lallemand et al. 2003). CSA being a highly 
hydrophobic drug, it has to be dissolved or loaded in certain media for proper delivery into the 
cornea. As our target for DED is the cornea and not intra ocular region, the primary goal is to 
sustain the formulation on the cornea for longer period for which SLN would help as it would 
entrap more drug and at the same time help in sustaining release of drug. Further, its conversion 
into in-situ gel would further help in sustaining the release.  
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The objective of the present investigation was to develop and characterize CSA 
loaded SLN (CSA-SLN) and it’s corresponding in-situ gel (CSA-SLN-IG) formulation, which 
would give controlled and sustained release of CSA. Accordingly, CSA-SLN was prepared and 
optimized based on physico-chemical characteristics. CSA-SLN converted to CSA-SLN-IG by 
the addition of gellan gum as gelling agent and evaluated for rheological characteristics and 
stability under several conditions.  
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CHAPTER II 
METHODOLOGY 
 
MATERIALS 
Tween® 80, Poloxamer 188 were acquired from Fischer scientific (Hampton, NH, USA). 
Precirol® ATO 5 (Glyceryldistearate) and Compritol 888® ATO (Glyceryldibehenate) was a 
generous gift sample from Gattefossé (Paramus, NJ, USA). Gellan gum was purchased from MP 
Biomedicals, LLC (Santa Ana, CA, USA). Cyclosporine A (CSA) was purchased from Sigma 
Aldrich (USA). Other chemicals and entities required for the project like HPLC grade solvents, 
centrifuge tubes, HPLC vials, scintillation vials were obtained from Fischer Scientific (Hampton, 
NH, USA). 
 
Preparation of Cyclosporine A loaded solid lipid nanoparticle (CSA-SLN) and in-situ gels 
(CSA-SLN-IG): 
PREPARATION OF CSA-SLN: 
CSA loaded solid lipid nanoparticle (CSA-SLN)was prepared using homogenization with probe 
sonication method(Gokce et al. 2008) as per the composition Table 1. It mainly consists of two 
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phases: the lipid phase and aqueous phase. Lipid phase consists of Precirol® ATO 5 and drug 
(CSA) whereas the aqueous phase consists of Tween® 80, Poloxamer 188 and double distilled 
water (mili-Q-water).  The lipid phase was melted at 65°C in a glass scintillation vial with 
continuous stirring at 2000 rpm. Simultaneously, in a separate vial aqueous phase was heated to 
the same temperature as the lipid phase. On attaining the temperature, the aqueous phase was 
added to the lipid phase drop by drop with constant stirring to  
 
get a premix. This premix was homogenized at high speed with T25 digital ultra-Turrax® 
(IKA®, USA) for 5 min at 24000 rpm to form a hot pre-emulsion. The pre-emulsion was placed 
in a beaker of ice (to reduce charring caused by excess heat) and then taken for probe sonication 
for 10 minutes at 40% amplitude with pulse 20sec on and 10sec off. The emulsion thus obtained 
was allowed to cool to room temperature to form CSA-SLN.  
 
Table 1: Composition of Cyclosporine a loaded solid lipid nanoparticle and in-situ gel of 
solid lipid nanoparticles 
Formulation 
Composition (%) 
w/v 
CSA-
SLN-C 
CSA-SLN-P CSA-SLN-
IG2 
CSA-SLN-
IG3 
CSA-SLN-
IG4 
Cyclosporine A 0.1 0.1 0.1 0.1 0.1 
 Compritol® 888 
ATO 
1.0 - - - - 
Precirol ® ATO 5 - 1.0 1.0 1.0 1.0 
Tween ® 80 0.5 0.5 0.5 0.5 0.5 
Poloxamer 0.5 0.5 0.5 0.5 0.5 
Gellan gum - - 0.2 0.3 0.4 
Water qs 10 ml 10 ml 10 ml 10 ml 10 ml 
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Production parameters like different rpm for ultra-Turrax®, and different ratios of lipid 
and surfactants in the formulation were also tested. Other parameters like  mixing time and probe 
sonication time were selected based on literature(Gokce et al. 2008). 
PREPARATION OF CSA-SLN-IG: 
 CSA –SLN loaded in situ gels were prepared in the same way as CSA-SLN. The only 
additional step was the addition of a gelling agent (Gellan gum) to the aqueous phase after 
homogenization. The composition of CSA-SLN-IG3 is given in table 1 
HPLC CHROMATOGRAPHIC CONDITIONS: 
A previously used high pressure liquid chromatography (HPLC) method was used for  
analysis of CSA-SLN and CSA-SLN-IG(Xu et al. 2013). HPLC system comprised of Waters® 
e2695 equipped with column oven, in-line degasser, auto sampler and PDI detector. The column 
used was C8Luna® 5µ (250 mm x 4.6 mm) and was protected by guard column. The mobile 
phase comprised of Acetonitrile (ACN): water: phosphoric acid (H3PO4) in ratio 75:25:0.1v/v/v 
respectively. The column temperature was set at 60°C using a column oven and the elution flow 
rate was 1ml/min. The Detection wavelength was set at 210 nm and auto sampler was maintained 
at 10°C.Injection volume for each sample was 10µL. 
CHARACTERIZATION OF SLN: 
Measurement of Particle size, Zeta potential (ZP) and PDI: 
Zeta potential is the overall charge of the nanoformulation and its magnitude (positive or 
negative) indicates the physical stability of the colloidal system as higher the magnitude, more 
the repulsion and less is the aggregation (Riddick 1968). 
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            The hydrodynamic radius, PDI and zeta potential(ZP) of the CSA-SLN formulation was 
determined by photon correlation spectroscopy at 25°C with 173°backscatter detection using a 
Zetasizer Nano ZS Zen3600 (Malvern Instruments, Inc., MA, USA). Clear disposable folded 
capillary cells (for particle size and PDI measurement) and special Zeta cells (for zeta potential 
measurement) were used to place the sample in Zetasizer. Particle size analysis data was 
evaluated based on the volume distribution for which about 10 µL of the sample was diluted up 
to 1000µL (100 times dilution) using double distilled (mili-Q) 0.2µm filtered water. 
 
DRUG CONTENT OF CSA-SLN AND CSA-SLN-IG 
Assay of CSA-SLN and CSA-SLN-IG was done by using lipid precipitation method. 
About 100 µL of CSA-SLN and CSA-SLN-IG formulation was extracted using 900 µL of ACN 
(as CSA is soluble in ACN) and sonicated for 15 minutes (for lipid precipitation). It was then 
centrifuged for 15 minutes at 13,000 rpm. The supernatant thus obtained was then analyzed for 
CSA content using the HPLC method mentioned above. 
 
DRUG-EXCIPIENT COMPATIBILITY STUDY - DIFFERENTIAL SCANNING 
CALORIMETRY (DSC) 
DSC analysis was used to check the crystallinity of the drug as well as the interaction of 
the drug with other lipid components. DSC of pure CSA, Precirol®ATO5 and physical mixture 
of Precirol®ATO5 and CSA (CSA: Precirol: 1:1) were obtained by DSC 250 (TA Instruments, 
USA). Approximately 5 mg of solid samples were hermetically sealed in the T0 aluminum pans 
and scanned from 0 to 225 °C with a heating rate of 10°C/min with constant nitrogen purging. 
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Empty pan was used as a reference. The thermograms thus obtained were overlayed and 
compared for results. 
 
MEASUREMENT OF pH: 
The pH of CSA-SLN and CSA-SLN-IG formulations was measured using pH meter 
(MettlerToledo, USA) after the preparation. The pH meter was calibrated every time using 
standard pH buffers 4.01, 7.00 and 10.01.  
RHEOLOGICAL AND IN VITRO GELLING CHARACTERISTICS OF CSA-SLN-IG: 
CSA-SLN-IG was evaluated for viscosity, gelling time and gel residence time.  
VISCOSITY: 
The viscosity measurement was carried out using a Brookfield cone and plate viscometer 
(LV-DV-II+ Pro Viscometer, Middleboro, USA). The distance between the cone spindle and 
sampler cup was maintained to the minimum and the temperature of the system was set to 34 ± 
0.2°C.  About 500 µL of the sample was placed in a cup and CPE 52 spindle was used at 
different shear stress to measure the viscosity. Two types of viscosity were calculated: a) 
viscosity for in-situ gel formulation alone and, b) viscosity of in-situ gel formulation with 
simulated tear fluid (STF) in the ratio of 50:7 respectively (as it mimics viscosity of formulation 
after application into eyes).Composition of STF : 0.678% of NaCl (sodium chloride), 0.0084% 
of CaCl2·2H2O(calcium chloride), 0.138% of KCl (potassium chloride), and 0.218 % of 
NaHCO3(sodium bicarbonate) in deionized water with pH of 7.0 ± 0.2 was maintained(Tatke et 
al. 2018).  Rheocalc® software was used to register the viscosities. 
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GEL FORMATION TIME: 
             Gel formation time is the time taken by CSA-SLN-IG to form gel when it comes in 
contact with STF without any agitation. STF was prepared as mentioned earlier. Gel Formation 
time of formulation with different concentration of gellan gum was determined by taking 50 µl 
of CSA-SLN-IG in 2 ml of STF (in glass vial) maintained at 34 °C temperature. Time taken for 
the formation of gel without any agitation was noted as gel formation time(Tatke et al. 2018). 
GEL RESIDENCE TIME: 
  Gel residence time is the time the formed gel remains intact in STF with continuous 
shaking. Fifty microliters of in situ gel formulation were added to 2 mL of STF in a glass vial 
and were then kept in a shaking water bath, maintained at a temperature of 34°C. Reciprocation 
rate of the shaker was kept at 100 times per minute. Time for gel breaking was noted(Tatke et al. 
2018). 
STABILITY STUDIES: 
        Stability studies of optimized CSA-SLN and CSA-SLN-IG were performed at 4°C, 25°C 
and 40°C temperature conditions. At specific time intervals, the formulations were evaluated for 
particle size, ZP, PDI and Assay according to the procedure mentioned earlier. 
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STERILIZATION: 
It is necessary that all ophthalmic formulations be sterile, making it a challenge for 
formulations. The two available methods are either sterile filtration or autoclave sterilization. 
Autoclave sterilization was done on both CSA-SLN and CSA-SLN-IG formulations to check if 
the formulations were stable during the autoclave process. About 5 mL of both CSA-SLN and 
CSA-SLN-IG formulation was taken in an autoclavable glass vial and placed in the autoclave 
(3850EL, Tuttnauer) at 121°C for 15 minutes at 15 psi pressure. Post-autoclave the formulations 
were checked for physical characteristics and compared to the pre-autoclave values.
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CHAPTER III 
RESULTS AND DISCUSSIONS 
 
Formulation development and optimization of CSA-SLNs: 
The CSA-SLN composition was selected as per the reported literature and slightly 
modified(Gokce et al. 2008).From the results, it has been observed that Tween 80® helps in 
reduction of aggregation as compared Poloxamer 188® alone(Gokce et al. 2008) and hence, 
Tween® 80 was added to the development of SLN. Tween® 80 and Poloxamer 188are non-ionic 
surfactants and  are known to be less toxic surfactant as compared to cationic surfactants 
(Lallemand et al. 2012). Also, Tween® 80 is known to be well-tolerated emulsifier. The 
concentration of surfactants used in the CSA-SLN formulation development was within the FDA 
Inactive Ingredient Database (IIG) system. 
Lower particle size gives more surface area and better interaction with body fluids 
because of which lower particle size and lower PDI are preferred. Thus, these parameters were 
considered of utmost importance while fixing the processing parameters and other composition 
concentrations. Numerous works of literatures are available on the CSA which helped us select 
Compritol® 888 ATO and Precirol® ATO 5 as the desired lipids of interest. Out of Compritol ®
12 
 
 and Precirol® ATO5, the later one gave smaller PS and PDI (Table 2) and thus Precirol® ATO5 
was selected as the lipid of interest.  
Processing parameter like Ultra-Turrax® speed was fixed at 16,000 and 24,000 rpm for 5 
minutes for pre-emulsion preparation of the CSA-SLN. From the results, pre-emulsion which 
were obtained at 24, 000 rpm showed better size reduction as compared to 16,000 rpm (Table 3). 
Therefore, 24,000rpmfor 5 minutes was selected for preparation of the CSA-SLN. Other 
processing parameters like probe sonication time and mixing time were optimized with slight 
modifications from the earlier report. 
The effect of lipid and surfactant concentrations on particle size and PDI were studied. 
From the results, as the concentration of lipid increases and surfactant decreases, increase in 
particle size and PDI were observed (Table 4). SLN prepared with 1%w/v of Precirol® ATO5, 
0.5%w/v of Tween® 80, and0.5% w/v of Poloxamer 188 resulted in lower PS and PDI andwere 
selected for CSA-SLN development. 
Table 1 shows the formulation composition for SLN and in-situ gel. Drug load of 0.1% was fixed 
as it is the maximum amount of drug load which shows a direct effect on dry eyes 
reduction,increasing the drug load more than 0.1%w/v does not increase the effect on treating 
DED. 
 
Formulation Size (nm) PDI Zeta (mV) Assay (%) 
CSA-SLN-C 631± 112.2 0.5± 0.08 -21± 0.5 90.1 ± 1 
CSA-SLN-P 121.20 ± 5.2 0.4 ± 0.04 -24 ± 1 95 ±0.5 
Table 2: Effect of different lipids (Compritol® 888 ATO and Precirol ® ATO 5) on 
Physical characteristics of Cyclosporine A solid lipid nanoparticles (mean ± SD, n=3) 
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           Table 3: Effect of Ultra-Turrax® rpm on particle size and PDI (mean ± SD. n=3) 
Ultra-Turrax® RPM Particle size(nm) ± S.D PDI ± S.D 
16000 140.80 ± 5.3 0.56 ± 0.06 
24000 121.20 ± 5.2 0.4 ± 0.04 
 
 
 
Table 4: Effect of lipid and surfactants concentration on physical characteristics of CSA-
SLN (mean ± SD, n=3) 
 
 
Compatibility Studies - DSC 
DSC studies were carried out to determine the purity, crystalline behavior and interaction 
of the drug with physical mixture.DSC thermograms of CSA, Precirol® ATO5 and physical 
mixture of CSA with Precirol® ATO5 are showed in Figure 1, 2 and 3 respectively. From the 
results, DSC thermogram of CSA showed an endothermic peak at 130.34ºC, and confirming its 
crystalline nature. A sharp melting point endothermic peak was observed for Precirol®ATO5 at 
56.6°C in individual as well as in the physical mixture, whereas a shift in melting point of CSA 
seen in thermograms of CSA with lipid physical mixture. The shift of CSA in the physical 
mixture and the short DSC peak for crystalline CSA is in accordance with the literature(Guada et 
al. 2015). The decrease in intensity of Precirol® ATO5 peak in the physical mixture is likely due 
Concentration (%) Physical characters 
Precirol® 
ATO5 
Poloxamer 
188 
Tween® 80 CSA Particle size (nm) PDI 
4.5 0.25 1.5 - 210 ± 4.8 0.5 ± 0.03 
1 0.5 0.5 - 119 ± 3.9 0.48 ± 0.02 
0.4 0.4 0.2 - 130 ± 4.6 0.60 ± 0.05 
1 0.5 0.5 0.1 121.2 ± 5.2 0.4 ± 0.04 
14 
 
to the decrease in the quantity of Precirol® ATO5in the physical mixture(1:1:Precirol® ATO5: 
CSA). Thus no interaction was found between the CSA and Precirol® ATO5 and thus they were 
compatible for SLN development.  
 
Figure 1:  DSC Thermogram for pure Cyclosporine A 
 
 
Figure 2: DSC Thermogram for pure Precirol® 
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Figure 3: DSC thermogram Cyclosporine A and Precirol® ATO5 physical mixture 
 
 
 
Stability Studies of CSA-SLN: 
The physical stability of CSA-SLN-P was checked for 30 days at refrigerator (4oC), room (25oC) 
and accelerated (40oC) temperature conditions. The results are presented in Table 5. The samples 
were checked for physical appearance, physical and chemical parameters like particle size, ZP, 
PDI and assay, respectively at predetermined time intervals. The formulation was found stable as 
there was no significant difference found in the results as well as there were no physical 
separation or breaking observed during storage at refrigerator and room temperatures upto 30 
16 
 
days. In the case of formulation stored at 40oC, precipitate formation (might be CSA) was 
observed after 15 days. 
 
 
 
 
 
 
 
 
 
pH of CSA-SLN 
The pH of the CSA-SLN-P formulation was checked every time during 
stability studies, in order to observe if there was any difference in pH. The pH of the CSA-SLN-
P comes in the range of 6-6.5, which is nearly equal to human tears(6.5-7.5) (Abelson, Udell, and 
Weston 1981). The pH of all formulations was within this range.  
 
CSA-SLN 
(P) 
 
4°C 
Particle size 
(nm) 
PDI Zeta Potential 
(mV) 
Assay (%) 
Day 1 121.2 ± 5.2 0.4 ± 0.04 -24 ± 1.0 95 ±0.5 
Day 15 119.0 ± 2.2 0.43 ± 0.02 -24 ± 0.5 94 ± 0.1 
Day 30 123.1 ± 3.4 0.35 ± 0.01 -23.62 ± 0.2 90 ± 0.3 
25°C 
Day 1 118.2 ± 8.0 0.55 ±0.05 -24 ±0.0 94± 0.5 
Day 15 120 ± 10 0.31 ± 0.06 -24.9 ± 1.5 92 ± 0.4 
Day 30 125.7 ± 5 0.41 ±0.13 -24.8 ± 1.2 91.5 ± 1.0 
40°C 
Day 1 135.6 ± 12.1 0.42± 0.09 -29.9 ±1.0 90 ±0.2 
Day 15 139 ± 1.1 0.41± 0.02 -26.4 ± 1.0 41 ±0.07 
Day 30 130 ± 1.5 0.36 ±0.06 -22.3 ± 0.0 38.32 ± 0.1 
Table 5: Stability studies of cyclosporine A solid lipid nanoparticles with Precirol® ATO5 at 
refrigerator (4°C), room (25°C) and accelerated (40°C) temperature conditions (mean ± SD. 
n=3) 
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Formulation development and Optimization of CSA-SLN in-situ gels (CSA-SLN-IG): 
The biggest advantage of an in-situ gel as compared to normal gel is that it is patient 
compliance, as it is easy to apply and forms gel immediately on contact with tear fluid. 
Conversion of CSA-SLN to in-situ gel would further enhance the retention of the formulation on 
the corneal surface. The critical quality attributes (CQA) for an in-situ gel is its rheological 
property and viscosity. CSA–SLN-IG was formulated using different percentage of gellan gum 
to get optimum CQA. Ideal viscosity for an ophthalmic solution lies between 25-50 cP(Uddin et 
al. 2017). Table6 presents various gellan gum concentration along with their viscosities and 
rheological properties. From the table it is evident that the formulation with 0.3%w/v gellan gum 
(CSA-SLN-IG3) has a viscosity of about 27.90 cP ± 2.8(without STF) and 1400 ± 6.9 cP (with 
STF) which shows that it forms strong gel after coming in contact with STF as compared to SLN 
with 0.2%w/v gellan gum. Even though CSA-SLN-IG4 has high viscosity with STF as compared 
to CSA-SLN-IG3, but it had lower assay and a viscosity (without STF) above the permitted 
range of 25-50cP(Tatke et al. 2018) because of which CSA-SLN-IG4 was not selected. CSA-
SLN-IG-3 (0.3%w/v gellan gum) also showed immediate gelling time and gel residence time 
greater than 24 h, thus CSA-SLN-IG3 was selected as an optimized formulation.  The reason 
behind gel formation is that gellan gum is an anionic polysaccharide and forms clear gel when 
comes in contact with ions present in the tear film. 
Thus, in accordance with results and inference discussed above, formulation CSA-SLN-
IG3 (0.3% gellan gum) was selected as an optimized formulation. 
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Stability studies for CSA-SLN-IG: 
CSA-SLN-IG3 was found stable for one month at refrigerated and room temperature 
conditions and no significant changes were observed in the assay, viscosity, gelling time, in-vitro 
gel residence time and pH. There was no physical separation also observed. 
Sterilization of CSA-SLN 
Post- production stability of CSA-SLN-P and CSA-SLN-IG3 were tested by subjecting to 
autoclave. The formulations were found to be stable until 30 days (last point tested) indicating 
the potential for sterilization using autoclave method. The sterilized formulations were evaluated 
for parameters like assay, entrapment efficiency, particle size, PDI, ZP and compared with the 
values before autoclaving. The results of pre and post-autoclave of CSA-SLN-P are shown in 
Table 7. Sterilization increased the particle size and decreased the PDI. Similarly, CSA-SLN-IG 
was also stable during the autoclave processing. 
Table 6: Rheological evaluation and physical characterization of in-situ gel of cyclosporine A 
solid lipid nanoparticle in-situ gel (mean ± SD, n=3) 
Formulation Gellan 
Gum 
(%w/v) 
In-vitro 
gelling 
time 
Gel 
Residence 
time (h) 
Viscosity 
(cP) 
Without 
STF 
Viscosity 
(cP) 
With STF 
Assay 
(%) 
CSA-SLN-
IG2 
0.2 Immediate >24 23.00 ±1.5 306.90±4.5 78 ± 0.1 
CSA-SLN-
IG3 
0.3 Immediate >24 27.90 ± 
2.8 
1400 ± 6.9 85 ± 0.5 
CSA-SLN-
IG4 
0.4 Immediate >24 120 ± 5.6 2278 ± 20 50 ± 0.5 
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Before Autoclave 
Particle size 
(nm) 
PDI Zeta Potential 
(mV) 
Assay (%) 
Day 1 125.8 ± 3.6 0.55±0.05 -24 ±0.0 94± 0.5 
Day 15 119 ± 1.2 0.31 ± 0.06 -24.9 ± 1.5 92 ± 0.4 
Day 30 125 ± 3 0.41 ±0.13 -24.8 ± 1.2 91.5 ± 1 
 After autoclave 
Day 1 165.1 ± 8.0 0.20 ±0.01 -25 ± 0.6 94 ± 0.02 
Day 15 160 ± 3.5 0.18± 0.04 -23.3 ±1 91.5 ± 0.11 
Day 30 158 ± 4.0 0.25 ±0 .06 -24.2 ± 0.7 90.8 ± 0.42 
Table 7: Effect of pre and post-autoclaving of CSA-SLN-P (mean± SD, n=3) 
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CONCLUSION 
 
In this study, CSA loaded solid lipid nanoparticles and corresponding in-situ gel 
was successfully formulated using Precirol® ATO5 as the lipid, Tween®80 and Poloxamer 188 
as surfactants and gellan gum as a gelling agent. The formulations were autoclavable and were 
stable for one month at different storage conditions. Further studies evaluating the in-vivo 
activity of the formulations are needed. 
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